G protein-coupled trace amine-associated receptor 1 (TAAR1) is expressed in several brain regions and modulates dopaminergic activity partially by affecting D2 dopamine receptor function. In vitro, the nonselective dopamine agonist apomorphine can activate mouse and rat TAAR1. The aim of the present study was to evaluate whether apomorphine activity at the rodent TAAR1 observed in in vitro studies contributes to its behavioral manifestation in mice. For this purpose, we compared the behavioral effects of a wide range of apomorphine doses in wild type (WT) and TAAR1 knockout (TAAR1-KO) mice. Apomorphine-induced locomotor responses (0.01-4.0 mg/kg) were tested in locomotor activity boxes, and stereotypic behavior at 5 mg/kg was tested by ethological methods. A gnawing test was used to analyze the effects of the highest dose of apomorphine (10 mg/kg). No statistically significant differences were observed between TAAR1-KO and WT mice following inhibitory pre-synaptic low doses of apomorphine. At higher doses (2.0-5.0 mg/kg), apomorphine-induced climbing behavior was significantly reduced in TAAR1 mutants relative to WT controls. Moreover, the lack of TAAR1 receptors decreased certain types of stereotypies (as reflected in by measures of the global stereotypy score, licking but not sniffing or gnawing) that were induced by high doses of apomorphine. These data indicate that apomorphine activity at TAAR1 contributes to some behavioral manifestations, particularly climbing, in rodents following high doses of this drug. The contribution of TAAR1 to apomorphine-induced climbing in rodents should be considered when apomorphine is used as a screening tool in the search for potential antipsychotics.
Introduction
Apomorphine is an archetype nonspecific dopamine agonist that activates both D1-like and D2-like receptors, with some preference for the latter subtypes (Millan et al., 2002) . At lower doses (<0.5 mg/kg), apomorphine generally inhibits motor activity in rodents in a dose-dependent manner; this effect is due to a preferential action at presynaptic D2-like autoreceptors, which attenuates endogenous dopaminergic activity through a feedback mechanism (Strombom, 1976; Gainetdinov et al., 1996) . At higher doses, apomorphine stimulates motor activity and induces climbing and stereotyped behaviors in rodents, predominantly due to actions at postsynaptic D1-like and D2-like receptors (Costall et al., 1978a; Nally et al., 2003) .
Most apomorphine-induced effects are clearly antagonized by typical antipsychotics that block D2-like receptors. In particular, the ability of a drug to antagonize apomorphine-induced climbing behavior in mice has been correlated with neuroleptic potentials (Protais et al., 1976; Costall et al., 1978a) , and this test has been used for decades as a screening tool to identify novel antipsychotics. Importantly, this test may be used to detect both classical neuroleptics and atypical agents (Puech et al., 1976; Costall et al., 1978a) . Although it is generally thought that apomorphine-induced climbing is the result of a direct action at dopamine receptors, Costall and colleagues (Costall et al., 1978b) noted that manipulations involving the serotonergic neurotransmitter system can modulate climbing behavior induced by apomorphine. They found that the nonselective serotonin agonist quipazine reduced or abolished climbing behavior and, conversely, that the serotonin antagonist methysergide enhanced the response. Furthermore, Costal and colleagues presented evidence that the GABAergic system is also involved in apomorphine-induced climbing behavior by showing that picrotoxin, a noncompetitive antagonist for the GABA A receptor chloride channels, induces a dose-dependent reduction in the intensity of apomorphine-induced climbing. In contrast, sodium valproate, a drug that inhibits GABA transaminases and thereby increases the concentration of GABAergic neurotransmission, failed to cause any changes in climbing behavior.
Trace amines are neurotransmitters whose role in regulating invertebrate physiology has been acknowledged for many decades (Philips et al., 1978) . Trace amines such as β-phenylethylamine and tyramine are structurally related to classic monoamines. Although they are found at low concentrations in the mammalian brain, it has been proposed that trace amines might be implicated in schizophrenia and depression (Boulton, 1980) . Trace amines could also affect the classic monoaminergic systems indirectly via an interaction with plasma membrane transporters, such as the dopamine transporter, in an amphetamine-like manner (Sotnikova et al., 2004) . However, only the identification of the trace amineassociated receptors (TAARs) have provided evidence for a direct biological effect of trace amines (Borowsky et al., 2001; Bunzow et al., 2001) . These receptors belong to the superfamily of G protein-coupled receptors. Intriguingly, human TAAR genes map to chromosome locus 6q23.1, which has been suggested to be a major potential susceptibility locus for schizophrenia . In humans, nine genes encoding TAARs are known .
TAAR1 is the best characterized member of the TAAR family (Grandy, 2007) . TAAR1 is a Gs-protein-coupled receptor; following activation, it increases intracellular cyclic adenosine monophosphate (cAMP) levels. In rodent and primate brains, TAAR1 mRNA and proteins were found in several brain areas, including the ventral tegmental area, the substantia nigra, the limbic system, the locus coeruleus, the dorsal raphe and the basal ganglia (Borowsky et al., 2001; Miller et al., 2005; Xie et al., 2007; Lindemann et al., 2008) . Several lines of evidence indicate that TAAR1 acts as a modulator of the dopaminergic system (Wolinsky et al., 2007; Lindemann et al., 2008; Sotnikova et al., 2009; Espinoza et al., 2011; Leo et al., 2014) . TAAR1-knockout (KO) mice display an enhanced response to dopaminergic stimuli, such as amphetamine (Wolinsky et al., 2007; Lindemann et al., 2008) , and an increased D2 receptor sensitivity (Wolinsky et al., 2007) , indicating that this mouse model could be relevant to schizophrenia (Wolinsky et al., 2007) . Conversely, TAAR1 activation, as obtained through the development of selective agonists, is able to decrease an abnormal dopaminergic response, such as the hyperlocomotion that is either induced by dopaminergic agonists or spontaneously present in mice lacking the dopamine transporter (Revel et al., 2011 (Revel et al., , 2013 . These observations led to the hypothesis that TAAR1 could be a novel target for the treatment of psychiatric disorders, such as schizophrenia, bipolar disorder and attention deficit hyperactivity disorder (ADHD) (Sotnikova et al., 2009; Revel et al., 2012 Revel et al., , 2013 . Intriguingly, it has been found that TAAR1 is activated not only by trace amines, such as β-phenylethylamine (PEA), tyramine, octopamine and tryptamine, but also by monoamine metabolites, such as the extracellular dopamine metabolite 3-methoxytyramine and a number of monoaminergic drugs, including the psychostimulant amphetamines and imidazolines (Bunzow et al., 2001; Hu et al., 2009; Sotnikova et al., 2010; Reese et al., 2014) . One such compound that activated rat TAAR1 expressed in HEK293 cells at a 10 μM concentration was apomorphine (Bunzow et al., 2001) .
To evaluate the putative agonistic activity of apomorphine at TAAR1, we performed a detailed characterization of the activity of apomorphine at TAAR1 using in vitro biochemical approaches, which involved cells transfected with mouse, rat, monkey and human TAAR1. Furthermore, we compared the behavioral effects of a wide range of doses (0.01-10 mg/kg) of apomorphine in wild type (WT) and TAAR1-KO mice.
Material and methods

Subjects
All procedures involving animals and their care were carried out in accordance with the guidelines established by the European Community Council (Directive 2010/63/ EU of September 22, 2010) and were approved by the Italian Ministry of Health. WT and TAAR1-KO mice were derived from crossing (over 10 generations) heterozygous TAAR1 C57BL6/129SvJ animals (Wolinsky et al., 2007) . Heterozygous mice were not analyzed in this study. Forty-six adult male C57BL6 mice were purchased from Charles River (Italy) for experiments with the TAAR1 agonist. Mice were housed 3-5/cage, maintained under standard lab conditions (12 h light/dark cycle, 21 ± 1°C and 40-70% humidity) with food and water provided ad libitum and tested between 12 and 20 wk of age. All experiments were conducted during the light phase. One hour before the behavioral experiments, the mice were habituated to the experimental room.
Radioligand-binding studies
Radioligand-binding assays were performed as previously described (Revel et al., 2011) 
using [
Measurements of cAMP
To validate apomorphine activity at TAAR1 in vitro, two independent approaches were used. First, an Upstate (Millipore, USA) immunoassay for cAMP was performed as described by Revel et al. (2011) . The second approach involved a Bioluminescence Resonance Energy Transfer (BRET) measurement of cAMP using an exchange protein activated by cAMP (EPAC) biosensor (Barak et al., 2008; Espinoza et al., 2011 Espinoza et al., , 2013 . In these experiments, all cell culture reagents and buffers were from Invitrogen (USA) and Sigma (USA), and fetal bovine serum (FBS) was from JRH Biosciences (USA). Coelenterazine h was purchased from Promega (USA). Plasmids containing the cDNA for the human trace amine associated receptors were obtained from the cDNA resource center at the University of Missouri-Rolla and the American Type Culture Collection (USA). The TAAR1 receptor and EPAC biosensor were generated as previously described by Barak et al. (2008) . Human embryonic kidney 293 cells (HEK293T) were maintained in Dulbecco's Modified Eagle's medium supplemented with 10% (vol/ vol) of FBS, 2 mM L-glutamine and 0.05 mg/ml of gentamicin at 37°C in a humidified atmosphere at 95% air and 5% CO 2 . Transient transfections were performed 24 h after cell seeding using Lipofectamine 2000, according to the manufacturer's protocol (Invitrogen). For the BRET experiments, 24 h after transfection, the cells were plated in poly-D-lysine-coated 96-well microplates (well assay plate with clear bottom, Fisher Scientific) at a density of 80 000 cells per well in phenol red free Minimum Essential Medium, which contained 2% FBS, 10 mM Hepes and 2 mM L-glutamine. The cells were then cultured for an additional 24 h. For the BRET assays, on the day of the experiment, the phenol red free medium was removed from the HEK293T cells and replaced by Phosphate Buffer Saline (PBS), which contained calcium and magnesium and 0.003% (wt/vol) ascorbic acid. To measure the cAMP variation using the EPAC biosensor, the assay was started by adding 10 μl of the cell-permeant substrate specific for Renilla luciferase, coelenterazine h, to the well to yield a final concentration of 5 μM, as described by Espinoza et al. (2011) . The agonistic activity of apomorphine was measured by adding it 10 min after the Rluc substrate. For the time course experiments, the plate was read immediately after the addition of the agonist and for approximately 30 min. All experiments were conducted in the presence of the phosphodiesterase inhibitor IBMX (Sigma) at a 200 μM final concentration, as previously described (Barak et al., 2008) . BRET readings were collected using an Infinite F500 instrument (Tecan, Switzerland), which allows the sequential integration of the signals detected in both the 465 to 505 nm and the 515 to 555 nm windows using filters with the appropriate band pass, and i-control software. The curve was fitted using a nonlinear regression and one site specific binding with GraphPad Prism 5.
Drugs R-(-)-Apomorphine hydrochloride hemihydrate (Sigma Aldrich, USA; m.w. = 312.19) was dissolved in a 0.2% solution of ascorbic acid. Quinpirole (3 mg/kg) and SKF 81297 (3 mg/kg) (Sigma Aldrich, USA; m.w. = 370.67 and 292.95, respectively) were dissolved in saline. The TAAR1 agonist RO5166017 (3 mg/kg) was provided by F. Hoffmann-La Roche (Switzerland); it was dissolved in a 5% solution of Tween 20 in saline. For all behavioral experiments, apomorphine was administered subcutaneously; all other drugs were administered via an intraperitoneal injection. All drugs were administered in a volume of 10 ml/kg. All solutions were made fresh daily.
Locomotor activity
Locomotion was evaluated using an automated Omnitech Digiscan apparatus (AccuScan Instruments, USA) under illuminated conditions. The apparatus included four open field monitors. Each Open Field monitor consisted of sets of 16 light beams arrayed in the horizontal X and Y axes. The hardware detected beams broken by the animal, which allowed the software to determine the location of the mouse in the cage. Cages were divided into four compartments (20 cm × 20 cm). Animals were tested individually for defined periods with 5-min intervals. Horizontal and vertical activities were expressed in terms of the number of beam breaks. In addition, the total distance covered and the vertical time parameters were measured.
Low doses of apomorphine (0.01-0.3 mg/kg) and vehicle were tested in the same group of animals after six daily habituation sessions. Nineteen animals were used in the tests: 10 TAAR1-KO and 9 WT mice. The dose test order was based on a within-subjects Latin Square design. Locomotor activity was recorded for 30 min, and the first 5 min was excluded from the analysis due to handling and injection procedures. Drug tests occurred two times per week in test sessions on Wednesdays and Saturdays.
The acute effects of apomorphine at higher doses (1.0, 2.0, 3.0 and 4.0 mg/kg) were evaluated in five independent groups of mice (9 WT and 10 KO, 7 WT and 7 KO, 10 WT and 8 KO, and 7 WT and 10 KO, respectively, and in 7 WT and 9 KO in the control vehicle group). Before drug administration, the mice were habituated to the activity monitor for 30 min. After drug injection, the locomotor activity of the animals was recorded for 90 min.
The acute effects of the TAAR1 agonist in combination with quinpirole and SKF 35393 on climbing behavior was tested in 7 independent groups of C57BL6 mice (saline group -6 animals; SKF 81297 -6 animals; quinpirole -6 animals; SKF 81297 + RO5166017 -7 animals; quinpirole + RO5166017 -4 animals; SKF 81297 + quinpirole + saline -8 animals; and SKF 81297 + quinpirole + RO5166017 -9 animals). The drugs were administered after 30 min of habituation to the locomotor boxes, and vertical activity was recorded for an additional 60 min.
Stereotypies
Mice were introduced individually to the boxes (20 × 20 cm, 40 cm high) with transparent walls. After 30 min of habituation, an apomorphine injection was administered. The testing session was terminated 35 min later. Behavior was recorded with a digital video camera for subsequent analysis and was rated every 5 min during a 30-s observation period. The scorer was unaware of the genotype or the treatment. Three distinct behaviors in response to apomorphine were observed and counted: sniffing, climbing and licking (protrusions of the tongue). The rating scale was modified for mice based on a previous study (Burban et al., 2010) . Stereotypies were scored as follows: 0 for the absence of stereotypies, 1 for some rare stereotypies, 2 for one or several frequent stereotypies and 3 for permanent stereotypies. In addition, a conventional 0-6-point total stereotypy scale was used to assess stereotypical behaviors in general: 0, asleep or inactive; 1, episodes of normal activity; 2, discontinuous activity with bursts of prominent sniffing and rearing; 3, continuous stereotypy, such as sniffing or rearing along a path; 4, stereotyped sniffing or rearing fixed in one location; 5, stereotyped behavior with bursts of licking or gnawing; and 6, continuous licking or gnawing (Budygin, 2007) .
Gnawing
Measurements of gnawing corrugated packing paper were performed as described previously (Tirelli and Witkin, 1995) with minor modifications. The corrugations were 5 mm wide, 2 mm high and separated from each other by 6.5 mm. Mice were tested singly in transparent, acrylic chambers (height, 14 cm; area, 38 cm × 16.8 cm); the floor consisted of a sheet of corrugated paper, with the corrugations facing upward. Each paper sheet was only used once. Testing started immediately after the injection of apomorphine at a dose of 10 mg/kg or vehicle and lasted 120 min. Gnawing was quantified by placing a transparent grid over the corrugations. A score of 1 was given for each grid square in which penetration or tearing was visible. The maximum possible score was 646.
Results
Apomorphine is a partial agonist of TAAR1 receptors in vitro
In radioligand-binding assays, apomorphine showed binding activity at TAAR1 in all species tested (mouse, rat, Cynomolgus monkey and human TAAR1 stably expressed in HEK293 cells), with the highest binding affinities (approximately 300 nM) observed at the mouse and rat TAAR1. To further characterize apomorphine activity towards TAAR1, we performed in vitro functional assays. TAAR1 is a G protein-coupled receptor that is coupled to a stimulatory G protein (Gαs), and its activation by an agonist induces an increase in the cAMP levels in the cell. First, we evaluated the effects of apomorphine on TAAR1 by employing a cAMP immunoassay in the same cellular preparations used for the radioligand binding assays. In these experiments, apomorphine displayed partial activity (59 and 79% of the PEA maximum response only at the mouse and rat TAAR1, respectively) (Table 1) .
Further, we used a BRET biosensor named EPAC to monitor cAMP fluctuations, and we transiently co-expressed this sensor with mouse and human TAAR1 in HEK293 cells (Barak et al., 2008; Salahpour et al., 2012) . Under these conditions, apomorphine stimulated cAMP production in cells transfected with TAAR1, but not in mock cells (Fig. 1a) , further confirming that it is able to stimulate TAAR1, as previously described (Bunzow et al., 2001 ). Dose-response experiments indicated that apomorphine reached its maximum effect at 10 μM, with an EC 50 of 310 nM (Fig. 1b) . By comparing its activity with that of the prototypical TAAR1 agonist PEA, it was evident that apomorphine behaved as a partial agonist, even as a relatively high efficacy partial agonist (75% of the PEA maximum response). No activity of apomorphine was found at the human TAAR1 at concentrations up to 10 μM.
Lack of TAAR1 does not affect locomotor effects of low doses of apomorphine
We first evaluated the effects of low (presynaptic) doses of apomorphine on horizontal activity in WT and TAAR1-KO mice (Fig. 2) . Animals in both groups showed decreased horizontal activity at doses of 0.03 and 0.1 mg/kg. As indicated by the one-way analysis of variance (ANOVA) analysis (main effect of drug dose), apomorphine treatment dose-dependently attenuated the horizontal activity of the animals (F(2,28) = 4,984, p < 0.05). The post-hoc analyses (Bonferroni's test) revealed that this effect of apomorphine was statistically significant for doses of 0.03 and 0.1 mg/kg, but not for a dose of 0.3 mg/kg (p = 1.00). The lack of an effect of a 0.3 mg/kg dose of apomorphine on locomotor activity is likely due to the putative activation of postsynaptic dopamine receptors by this dose of the drug. Importantly, TAAR1-KO mice did not show any difference from the WT control group (F(2,28) = 4,984, p < 0.05). Thus, the lack of TAAR1 had no measurable effect on the action of low doses of apomorphine, as both genotypes reacted to apomorphine similarly. We did not detect a difference in the locomotor activity of TAAR1-KO and WT mice treated with apomorphine at a dose of 1 mg/kg (data not shown).
TAAR1-KO mice show reduced apomorphine-induced climbing
In subsequent tests, we evaluated the acute effects of higher doses of apomorphine (2-4 mg/kg), which are known to induce characteristic climbing behaviors in rodents (Costall et al., 1978b; Wilcox et al., 1980) . As presented in Fig. 3d , at these doses, apomorphine clearly produced a dose-dependent increase in the amount of vertical time in WT animals (F(3,56) = 19.558, p < 0.001).
The lack of TAAR1, however, dramatically decreased the climbing effect of apomorphine (F(1,56) = 15.665, p < 0.001). Post-hoc analyses (Bonferroni's test) revealed KO, knockout. that the decrease in apomorphine-induced climbing was statistically significant for the doses of 3 and 4 mg/kg. As presented in Fig. 3b , c, post-hoc analyses (Bonferroni's test) after an additional two ANOVAs with repeated measures (within subjects factor of time and between subjects factor of mutation) revealed that climbing induced by 3 and 4 mg/kg apomorphine significantly decreased in TAAR1-KO mice at the time points of 35-80 and 90 min and of 40-55 and 105 min, respectively.
Reduced stereotypies in TAAR1-KO mice after apomorphine at 5 mg/kg dose Next, using an ethological approach, we evaluated the effects of 5 mg/kg apomorphine, which is a dose that normally produces not only climbing but also a complex set of stereotypies (Sluyter et al., 1995) . Figure 4a -d shows the effects of the administration of 5 mg/kg apomorphine on stereotyped behaviors in WT and TAAR1-KO mice. Similar to the previous series of experiments, KO mice showed a decreased amount of climbing at the 50th, 60th and 65th min (F(3,34) = 4.258, p < 0.05), which was revealed by a Bonferroni's post-hoc test. The general level (GS) of apomorphine-induced stereotypes was also significantly decreased in TAAR1-KO mice after the 40th min (F(5,59) = 6.035, p < 0.01), as revealed by a oneway ANOVA followed by a Bonferroni's test. In the same way, the lack of TAAR1 receptors decreased apomorphine-induced licking at the 60th and 70th min (F(3,34) = 4.258, p < 0.05; post-hoc Bonferroni's test). In contrast, sniffing behavior induced by apomorphine 5 mg/kg, s.c., was not altered in TAAR1-KO mice (F(3,38) = 0.508, p = 0.71).
Lack of TAAR1 receptors does not affect apomorphine-induce gnawing
The effects of apomorphine (10 mg/kg, s.c.) on gnawing scores in WT and TAAR1-KO mice are shown in Fig. 4e . Post-hoc analyses (Bonferroni's test) revealed that at the highest tested dose, apomorphine induced significant intensive gnawing in both genotypes (Ps < 0.05, compared to saline treated controls groups), in accordance with previous works (Hedley and Wallach, 1983; Geter-Douglass et al., 1997) . In this test, TAAR1-KO animals did not show any difference from WT mice (F(1,26) = 0,21, p = 0.89).
It should be noted that Tirelli and Witkin (1995) did not detect apomorphine-induced gnawing in C57/Bl6J mice when the drug was tested in cages with corrugated paper on the floor. However, we were able to reliably detect gnawing following a 10 mg/kg s.c. administration (Bonferroni's test) , relative to the corresponding wild-type (WT) control group. Please note that global stereotypy score (a) was analyzed according to Budygin (2007) while sniffing (b), climbing (c) and licking (d) according to Burban et al. (2010) with minor modifications. (e) Gnawing was quantified by counting of visible penetration or tearing of corrugated paper. Testing started immediately after s.c. injection (10 mg/kg, s.c.) and lasted 120 min. Gnawing was quantified by placing a transparent grid over the corrugations. A score of 1 was given for each grid square in which penetration or tearing was visible. Results are expressed as mean ± S.E.M. *p < 0.05 (Bonferroni's test), relative to the corresponding saline-treated control group. KO, knockout. of apomorphine both in WT and mutant mice (on a mixed 129SvJ × C57Bl6J background); we used a modified method involving different dimensions of the chamber and a larger grid square design.
Activation of TAAR1 receptors increases climbing induced by co-activation of D1 and D2 dopamine receptors
Finally, to confirm the role of TAAR1 in climbing behavior and exclude the possibility that reduced climbing following apomorphine is not related to the general inability of TAAR1-KO mice to climb, we employed a pharmacological approach in normal mice. Thus, we evaluated the effects of the selective activation of TAAR1 by the agonist RO5166017 on climbing induced by the combination of a D1 dopamine agonist, SKF 38393, and a D2 dopamine agonist, quinpirole, in C57Bl6 mice. In agreement with a previous report (Moore and Axton, 1988) , treatment with the combination of D1 and D2 dopamine agonists induced climbing behavior in mice (F(6,39) = 3.048, p < 0.05), but at levels that were less pronounced compared with apomorphine-induced climbing. A posthoc analyses (Bonferroni's test) revealed that mice treated with the combination of quinpirole and SKF 38393 spent more time in a vertical position than did vehicle or single drug-treated control animals (p < 0.05). As illustrated in Fig. 5 , the additional activation of TAAR1 receptors significantly increased the climbing that was induced by the simultaneous stimulation of both types of dopamine receptors (one-way ANOVA with a repeated measurement interaction factor (F(6,100) = 2.598, p < 0.05)). Notably, the TAAR1 agonist did not induce climbing alone or potentiate the effects of SKF 38393 or quinpirole administered separately. A post-hoc analyses revealed that at 55-85 min of observation, mice treated with the combination of quinpirole, SKF 38393 and an agonist of TAAR1 receptors showed a significantly higher level of climbing than did animals treated with the combination of quinpirole, SKF 38393 and vehicle (p < 0.05).
Discussion
In this study, we investigated the putative involvement of TAAR1 in the effects of apomorphine. First, we confirmed and extended the pioneering observation by Bunzow et al. (2001) by showing that mouse and rat TAAR1 can be affected by apomorphine in vitro, with an EC 50 s in the 300 nM range. Notably, this activity of apomorphine appears to be weak in monkey and human TAAR1. Second, to verify whether this activity has functional consequences in vivo, we evaluated the behavioral effects of a wide range of doses (0.01-10 mg/kg) of apomorphine in WT and TAAR1-KO mice. In agreement with numerous previous reports (Strombom, 1976; Hedley and Wallach, 1983; Philp et al., 1986; Geter-Douglass et al., 1997; Gunzler et al., 2007) , a typical picture of the effects of different doses of apomorphine in WT mice was observed. Pre-synaptic low doses (<0.5 mg/kg) of apomorphine significantly inhibited locomotor activity (Strombom, 1976; Gunzler et al., 2007) . Higher doses (2.0-4.0 mg/kg) induced climbing behavior (Costall et al., 1978a; Nally et al., 2003) . At a dose of 5.0 mg/kg, a complex set of apomorphine-induced stereotypes was observed (Philp et al., 1986) . At the highest dose tested (10 mg/kg), apomorphine elicited gnawing responses in mice (Hedley and Wallach, 1983; Geter-Douglass et al., 1997) .
The lack of TAAR1 significantly affected some characteristic behaviors induced by apomorphine. Thus, TAAR1-KO animals had a significant deficit in apomorphine (2-5 mg/kg)-induced climbing and showed a significantly lower level of apomorphine (5 mg/kg)-induced licking and global stereotypy score. Notably, the lack of TAAR1 did not affect the hypolocomotor effects of low doses of apomorphine, sniffing induced by apomorphine at 5 mg/kg or gnawing following apomorphine at 10 mg/kg. Thus, apomorphine activity at TAAR1 receptors seems to contribute only to some specific forms of stereotypies, with climbing being predominately affected. To further verify the role of TAAR1 in climbing behavior and to exclude the potential contribution of functional or developmental compensations that might occur in transgenic mice, we tested whether the pharmacological activation of TAAR1 by RO5166017 can affect climbing induced by a combination of selective D1 and D2 agonists in C57BL/6 mice. In these experiments, the activation of TAAR1 receptors significantly increased climbing induced by the simultaneous activation of D1 and D2 dopamine receptors. This result is in accordance with the apomorphine-induced climbing deficit observed in TAAR1-KO animals. It should be noted that altered responses to apomorphine in TAAR1-KO mice could be due to the partial activity of apomorphine at TAAR1 but could also be determined by the altered dopaminergic function in these mice. It is well known that apomorphine effects in animals are primarily determined by the co-activation of D1 and D2 dopamine receptors. There are several lines of evidence indicating that TAAR1 modulates dopaminergic activity. In particular, mice lacking TAAR1 provided important information on TAAR1-related dysfunctions and the contributions of TAAR1 to dopamine regulated behaviors. It has been reported that TAAR1-KO mice have enhanced sensitivity to d-amphetamine, both in locomotor tests and in in vivo microdialysis investigations of striatal extracellular dopamine level (Wolinsky et al., 2007; Lindemann et al., 2008 ). An increased level of the high affinity state D2 dopamine receptors in the striatum (Wolinsky et al., 2007) and reduced catalepsy following the D2 dopamine receptor antagonist haloperidol were also observed in TAAR1-KO mice (Espinoza et al., 2011) . Furthermore, recent data suggested that TAAR1 and D2R can interact functionally by modulating the cAMP level and directly by the formation of a heterodimer in live cells (Espinoza et al., 2011) . Pharmacological studies with newly identified TAAR1 agonists are generally in agreement with the observations in TAAR1-KO mice. The TAAR1 partial agonist RO5166017, a potential antipsychotic agent, decreased cocaine-induced hyperlocomotion in rats and mice and attenuated dopamine-dependent hyperactivity in mice lacking the dopamine transporter (Revel et al., 2011) . It should be noted that the general inhibitory role of TAAR1 with regards to dopamine-related behaviors would suggest that the apomorphine effects in TAAR1-KO mice should be increased; however, we observed a decrease in apomorphine-induced stereotypies and climbing. Thus, these results are more consistent with the lack of a direct activity of apomorphine at TAAR1 in these mutants as indicated in our in vitro (binding affinity, cAMP response as measured by immunoassay and BRET) experiments. Furthermore, we were able to demonstrate that the acute activation of TAAR1 enhances the climbing response to D1/D2 dopamine receptor stimulation in normal animals. Taken together, these data suggest that TAAR1 contributes to certain effects of high doses of apomorphine effects via a direct, rather than indirect, mechanism involving alterations in dopaminergic transmission. Furthermore, these observations demonstrate that in concordance with previous findings (Costall et al., 1978a) , other neurotransmitter systems, in addition to dopamine, can be involved in the effects of apomorphine. For example, it has been reported that the nonselective 5HT receptor agonist quipazine attenuated apomorphine-induced climbing behavior, and the serotonergic antagonist/ partial agonist methysergide intensified this reaction (Costall et al., 1978a) . Further, the noncompetitive GABA A receptor antagonist picrotoxin dose-dependently reduced climbing behavior induced by apomorphine. The multiplicity of apomorphine targets is very intriguing because apomorphine is the only dopamine receptor agonist that has demonstrated antipsychotic activity (Del et al., 1986) .
Finally, these results indicate that while TAAR1 is only weekly affected by apomorphine in humans, it can be directly activated by apomorphine in rodents with significant functional consequences. This effect in rodents should be considered when apomorphine-induced climbing is used as a screening tool in preclinical behavioral pharmacology tests. It is possible that this screening test in rodents could yield the identification of potential antipsychotic compounds with at least partial TAAR1 activity, which may have unique pharmacological profiles in humans.
